Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Cyproheptadine in cats
Cyproheptadine is sometmes used in cats to stimulate their appetite. What about the distribution in the body after oral or intravenous application? The results of this study give interesting informations...

The objective of this study including 6 healthy cats was to determine disposition of cyproheptadine hydrochloride in cats after intravenous or oral administration of a single dose. A randomized crossover design was used, and each cat was studied after intravenous (2 mg) and oral (8 mg) administration of cyproheptadine.

Blood samples were collected at fixed time intervals after drug administration, and serum cyproheptadine concentration was determined by means of polarized immunofluorescence.

RESULTS: Mean (+/- SD) residence time was significantly longer after oral (823 +/- 191 minutes) than after intravenous (339 +/- 217 minutes) administration, but no significant differences were detected between other pharmacokinetic parameters after oral and intravenous administration.

Mean +/- SD oral bioavailability was 1.01 +/- 0.36.

Mean elimination half-life after oral administration was 12.8 +/- 9.9 hours. Peak extrapolated cyproheptadine concentration was 669 +/- 206 ng/ml. Only 1 cat developed adverse effects (transient vocalization).

CONCLUSIONS: Cyproheptadine appeared to be well tolerated in cats and had high bioavailability after oral administration. The mean elimination half-life of 12 hours indicated that approximately 2.5 days must elapse to achieve steady-state concentrations of cyproheptadine after oral administration of multiple doses. A 12-hour dosing interval is acceptable, but an 8-hour interval may be indicated for some cats.

On the basis of pharmacokinetic parameters determined in this study, the oral form of cyproheptadine appears to be suitable for use in clinical trials to treat anorexia in cats. Its half-life is compatible with once or twice daily dosing.


Source: Norris CR, Boothe DM, Esparza T, Gray C, Ragsdale M. (1998): Disposition of cyproheptadine in cats after intravenous or oral administration of a single dose. In: Am J Vet Res. 1998 Jan;59(1):79-81.



Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

In-hospital ECG versus 24-hour Holter in dogs with atrial fibrillationmembers
Atrial fibrillation is a potentially life-threatening condition which requires good management including good monitoring. The objective of this study was to determine if the in-clinic ECG-derived heart rate could predict the at-home Holter-derived 24-hour average heart rate (Holter24h), and whether it is useful to identify slow versus fast atrial fibrillation in dogs.

  • Novel radiation therapy for inoperable massive hepatocellular carcinoma members
  • Red blood cell storage lesion - an updatemembers
  • Coagulation abnormalities in dogs following severe acute traumamembers
  • Ultrasound-guided epidural access at the lumbo-sacral spacemembers
  • Thrombelastometry in dogs undergoing orthopedic surgerymembers
  • COX-2 inhibitors after phacoemulsification cataract removalmembers
  • First report of achromatopsia in related Labrador Retriever without CNGB3 mutations members
  • Acute kidney injury in severe sepsismembers
  • First description of orbital pneumatosis in a young catmembers
  • Serum antibodies to βA1-crystallin and cataract formation in Cocker spanielsmembers
  • Canine osteosarcoma cells and aurora kinase inhibitorsmembers
  • Long-term compassionate use of oclacitinib in dogs with allergic skin diseasemembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2013 VetContact GmbH
    All rights reserved